Nadia Harbeck, MD, PhD, on Early Breast Cancer: Benefit of a De-escalated Regimen
2021 ASCO Annual Meeting
Nadia Harbeck, MD, PhD, of Ludwig Maximilian University of Munich, discusses results from the ADAPT HR–/HER2+ trial, which showed, for the first time, improved pathologic complete response and survival in patients with early breast cancer who were treated weekly with a de-escalated 12-week regimen of neoadjuvant paclitaxel plus pertuzumab and trastuzumab (Abstract 503).
The ASCO Post Staff
Peter C. Black, MD, of the Vancouver Prostate Centre, University of British Columbia, reviews three studies on early detection and treatment of Black patients with prostate cancer: a large-scale analysis of genomic profiling; the use of PSA screening; and integrating a patient-specific genomic classifier to improve risk classification and treatment recommendations for Black men (Abstracts 5003, 5004, and 5005).
The ASCO Post Staff
Vamsidhar Velcheti, MD, of New York University, discusses overall survival and exploratory subgroup analyses from the phase II CodeBreaK 100 trial, which evaluated the use of sotorasib in pretreated KRAS G12C–mutant non–small cell lung cancer (Abstract 9003).
The ASCO Post Staff
Sibylle Loibl, MD, PhD, of the German Breast Group, discusses results from the phase III GeparNUEVO study, which investigated neoadjuvant durvalumab in addition to anthracycline/taxane-based neoadjuvant chemotherapy in patients with early triple-negative breast cancer (Abstract 506).
The ASCO Post Staff
Peter H. O’Donnell, MD, of The University of Chicago, discusses response and survival results from the phase II KEYNOTE-052 study, which showed that after up to 5 years of follow-up, pembrolizumab continued to elicit clinically meaningful, durable antitumor activity in cisplatin-ineligible patients with advanced urothelial cancer (Abstract 4508).
The ASCO Post Staff
Sumanta K. Pal, MD, of City of Hope, discusses results from a phase II study that sought to determine whether adding berzosertib, a selective ATR inhibitor, to the standard upfront chemotherapy regimen of cisplatin with gemcitabine may improve outcomes in patients with metastatic urothelial carcinoma (Abstract 4507).
